In 2012, the World Health Organization (WHO) set the elimination of Chagas disease intradomiciliary vectorial transmission as a goal by 2020. After a decade, some progress has been made, but the new 2021-2030 WHO roadmap has set even more ambitious targets. Innovative and robust modelling methods are required to monitor progress towards these goals. We present a modelling pipeline using local seroprevalence data to obtain national disease burden estimates by disease stage. Firstly, local seroprevalence information is used to estimate spatio-temporal trends in the Force-of-Infection (FoI). FoI estimates are then used to predict such trends across larger and fine-scale geographical areas. Finally, predicted FoI values are used to estimate disease burden based on a disease progression model. Using Colombia as a case study, we estimated that the number of infected people would reach 506 000 (95% credible interval (CrI) = 395 000-648 000) in 2020 with a 1.0% (95%CrI = 0.8-1.3%) prevalence in the general population and 2400 (95%CrI = 1900-3400) deaths (approx. 0.5% of those infected). The interplay between a decrease in infection exposure (FoI and relative proportion of acute cases) was overcompensated by a large increase in population size and gradual population ageing, leading to an increase in the absolute number of Chagas disease cases over time. This article is part of the theme issue 'Challenges and opportunities in the fight against neglected tropical diseases: a decade from the London Declaration on NTDs'.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440172 | PMC |
http://dx.doi.org/10.1098/rstb.2022.0278 | DOI Listing |
Clin J Am Soc Nephrol
September 2024
Department of Internal Medicine, Institute of Kidney Disease Research, Yonsei University College of Medicine, Seoul, Republic of Korea.
Background: Few studies have globally assessed the cardiovascular disease (CVD) mortality burden attributable to secondhand smoke. We aimed to address this research gap.
Methods: We used a systematic analysis design using data from the Global Burden of Disease Study 2019.
PLoS One
December 2024
PrismHealth North Texas, Dallas, Texas, United States of America.
Treatment of HIV has historically required taking daily oral antiretroviral therapy (ART). A recent alternative to daily oral ART is long-acting injectable ART with cabotegravir plus rilpivirine, administered monthly or every 2 months. The purpose of this qualitative study was to evaluate the concept relevance and interpretability of five previously developed questions: one treatment preference question and four questions designed to assess how the emotional burden associated with HIV treatment impacts treatment preferences.
View Article and Find Full Text PDFInt J Environ Health Res
December 2024
School of Public Health, Binzhou Medical University, Yantai, Shandong Province, PR China.
Research on geographic and socioeconomic disparities of NO attributed mortality burden is limited. This study aims to quantify the geographic and socioeconomic differences in the association between long-term exposure to NO and mortality burden in China. We estimated the all-cause mortality burden of adults over 16 years old attributable to NO exposure above 10 µg/m for 231 Chinese cities from 2015 to 2019, and geographic and socioeconomic differences .
View Article and Find Full Text PDFJAMA Health Forum
December 2024
Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.
Importance: More than one-quarter of US residents live in states or localities that restrict sales of flavored electronic nicotine delivery systems (ENDS), often as a means to reduce youth vaping. Yet, how these policies affect young adult vaping and smoking remains unclear.
Objective: To estimate the effects of ENDS flavor restrictions on ENDS use and cigarette smoking among young adults (age 18-29 years) in the US.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!